Novartis Lp(a) Drug Misses Heart Attack Goal
Pelacarsen failed to significantly reduce major cardiovascular events versus placebo in the Phase III HORIZON trial, presented at AHA Scientific Sessions 2026.
Updated on Nov. 22, 2026 in Heart Disease

Novartis's pelacarsen did not significantly reduce major adverse cardiovascular events compared with placebo in the Phase III Lp(a) HORIZON trial, despite lowering lipoprotein(a) levels by 78.4% at 12 months. Results were presented at the American Heart Association Scientific Sessions 2026.
Why it matters
Lp(a) is a largely genetically determined, causal risk factor for atherosclerotic heart disease that conventional cholesterol drugs barely affect, so the trial's miss tests whether lowering the molecule translates into fewer heart events. The result creates uncertainty for an emerging market of Lp(a)-lowering therapies.
The trial's primary outcome, measured against placebo in patients with established cardiovascular disease and elevated Lp(a), showed a hazard ratio of 1.02 (95% CI 0.90-1.15; P=0.69) despite a 78.4% drop in lipoprotein(a) levels. Whether the lipid reduction can produce benefit through alternative therapies or earlier treatment remains unknown.
The players
Novartis
A Swiss multinational pharmaceutical company headquartered in Basel, Switzerland, and developer of pelacarsen.
American Heart Association
A U.S.-based nonprofit organization focused on cardiovascular health, whose Scientific Sessions hosted the presentation of the trial results.
The details
Pelacarsen, an antisense oligonucleotide that inhibits apolipoprotein(a) production, was evaluated in patients with established cardiovascular disease and elevated Lp(a). The trial found the drug did not significantly reduce major adverse cardiovascular events compared with placebo, and no significant benefit was observed among patients with baseline Lp(a) levels of at least 90 mg/dL.
Timeline
2026: Lp(a) HORIZON results presented at the American Heart Association Scientific Sessions
12 months: Period over which pelacarsen's 78.4% reduction in Lp(a) was measured
Health Landscape
Lp(a) is a largely genetically determined, causal risk factor that conventional lipid-lowering therapies barely move, so pelacarsen's miss in the HORIZON trial raises questions about the whole class of molecule-targeting drugs. Competing siRNA therapies from Eli Lilly (lepodisiran) and Amgen (olpasiran) have reduced Lp(a) by more than 95%, and their outcomes will test the same hypothesis.
For people with elevated lipoprotein(a), the trial means no approved drug has yet shown it prevents heart events by lowering this molecule, so standard risk management remains the current approach. Anyone with a family history of early heart disease should discuss Lp(a) testing with a clinician, since the level is largely inherited and not reduced by typical cholesterol medications.
The takeaway
A drug that dramatically lowers a genetically driven heart risk marker did not prevent heart events in this trial, a reminder that a biomarker reduction alone does not guarantee clinical benefit. Ongoing outcomes studies of competing therapies will determine whether the approach ultimately works.
Further reading
For broader context on the condition at the center of this trial, see Heart Disease.
Source note: This article includes information reported by Globaldata.



